Compare the efficacy of combination therapy of Deferasirox and Deferiprone in reducing iron load in patients with transfusion-Dependent ß-Thalassemia.

Phase 3

• Conditions: transfusion-Dependent ß-Thalassemia.; Beta thalassemia

• Registration Number: IRCT20190106042262N1
• Lead Sponsor: Esfahan University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 25 March 2019

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 108

Inclusion Criteria

All Patients with transfusion-Dependent ß-Thalassemia with ferritin more than 1000
All Patients with transfusion-Dependent ß-Thalassemia who were not treated with combination iron chelators
All Patients with transfusion-Dependent ß-Thalassemia with heart and liver iron load
All Patients with transfusion-Dependent ß-Thalassemia with normal liver and renal function
All Patients with transfusion-Dependent ß-Thalassemia with age more than 10 years

Exclusion Criteria

Gastrointestinal problem before research

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Heart and liver iron concentration. Timepoint: At the start of research and six month later. Method of measurement: Magnetic resonance imaging T2*.

Secondary Outcome Measures

Name	Time	Method
Ferritin. Timepoint: At the start of research and third and sixth of study. Method of measurement: Serum ferritin level.